



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd
Addysgu Powys
Powys Teaching
Health Board

Information Governance Team
Monnow Ward
Bronllys Hospital
Bronllys
Brecon
Powys LD3 0LY

Email: Powys.FOI@wales.nhs.uk
Tel: 01686 252170 / 01874 442071

Our ref: IG/FOI/FOI.250.26

17 July 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 23 June 2026 and subsequent clarification received on 15 July 2026 to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

Your Freedom of Information (FOI) Request:

Under the Freedom of Information Act 2000, I am requesting information regarding the prescribing and dispensing of dupilumab (Dupixent) - all strengths and formulations, however it is classified in your systems, for patients prescribed, approved and dispensed at Betsi Cadwaladr University Health Board.

I understand from a response issued by another Welsh Health Board (Hywel Dda UHB, ref FOI.20573/26) that dupilumab is commissioned at Health Board level rather than through the NHS Wales Joint Commissioning Committee. This request is therefore directed to the data your Health Board holds directly.

All requested data should be provided as monthly aggregate counts. Please apply standard NHS statistical disclosure control rules and suppress any patient-count cell below 5. Where indication-attribution is not routinely held in a single source, please provide what is available from your standard reporting and indicate which fields are not held.

Q1. New patient initiations by indication, monthly.

For each calendar month from January 2022 to the date of this request, please provide the number of patients newly approved for / newly initiated on dupilumab at your Health Board, broken down by the indication recorded at the point of approval (for example, as captured on the high-cost-drug / Blueteq approval form).

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661

Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

Categories of interest:

- Severe asthma (eosinophilic / type-2 high)
- Chronic obstructive pulmonary disease (COPD)
- Atopic dermatitis
- Chronic rhinosinusitis with nasal polypsis (CRSwNP)
- Eosinophilic oesophagitis (EoE)
- Prurigo nodularis
- Other / not recorded

Q2. Prevalent patient counts by indication, monthly.

For the same period, please provide the total number of patients receiving ongoing dupilumab treatment at each month-end, broken down by the same indication categories as Q1.

Q3. Total dispensed volume and spend, monthly.

For the same period, please provide the total monthly dispensed quantity of dupilumab, broken down by strength and pack/device type (e.g. 200mg and 300mg pre-filled pen and pre-filled syringe packs), and the total monthly spend (£, ex VAT).

I appreciate that actual contracted/net unit prices may be considered commercially sensitive. If you consider the spend figure exempt (e.g. under s.43), I would be grateful if you would instead provide, in order of preference:

- (a) spend calculated at published list / drug-tariff price; or
- (b) spend in banded ranges; or
- (c) the dispensed volumes alone, by strength and pack size.

For reference, Hywel Dda UHB disclosed the monthly dispensed volumes by pack size under FOI.20573/26, so I would expect at minimum the volume element of this question to be answerable.

Notes on scope and the s.12 cost limit: if any question, as asked, would breach the s.12 cost limit, I would welcome a steer on a narrower scope answerable within the limit for example a rolling 24-month period, a single indication split (severe asthma vs all other combined), or annual rather than monthly totals. Where routine reports already answer all or part of this high-cost-drug returns, biologic dashboards, board papers those existing reports are an acceptable response.

Please respond to the email address below. I confirm I am content for the response to be issued under the Open Government Licence (OGL v3.0).

Clarification Requested on 24 June 2026

Thank you for your request. We note from the first paragraph that your request appears to be directed to Betsi Cadwaladr University Health Board. Please can you therefore confirm if this request is for Powys Teaching Health Board? Please note that we have today responded to a similar request from your company received on 2nd June 2026 (FOI.225.26). In light of this, please let us know if we can proceed to close your request.

Clarification response on 15 July 2026:

That is correct. This is for Powys Teaching Health Board.

Powys Response:

I can confirm that our response remains unchanged as set out in our final response FOI.225.26 issued to your company on 24 June 2026.

If any part of your request hasn't been answered by this response, please submit a new request addressing the missing information only.

If you are dissatisfied with the handling or response to your request, you have the right to ask for an internal review. Should you wish an internal review, please quote the reference number and send your correspondence to the above address.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>


Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.